Kyntra Bio, Inc. (KYNB)

NASDAQ: KYNB · Real-Time Price · USD

7.34

+0.02 (0.27%)

Apr 20, 2026, 4:00 PM EDT - Market closed

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
The Discovery, Development and Commercialization of Novel Therapeutics	6.44M	29.62M	46.80M	140.73M	235.31M
The Discovery, Development and Commercialization of Novel Therapeutics Growth	-78.26%	-36.71%	-66.74%	-40.19%	33.46%
Total	6.44M	29.62M	46.80M	140.73M	235.31M
Total Growth	-78.26%	-36.71%	-66.74%	-40.19%	33.46%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
United States	-	26.11M	12.96M	12.52M	46.12M
United States Growth	-	101.48%	3.53%	-72.86%	-29.24%
Europe	5.64M	6.27M	9.55M	33.82M	131.24M
Europe Growth	-10.00%	-34.34%	-71.77%	-74.23%	631.00%
Japan	797.00K	-2.85M	15.87M	9.76M	2.31M
Japan Growth	-	-	62.51%	323.60%	-88.37%
China	-	91.00K	8.43M	84.63M	55.64M
China Growth	-	-98.92%	-90.04%	52.10%	-24.16%
Total	6.44M	29.62M	46.80M	140.73M	235.31M
Total Growth	-78.26%	-36.71%	-66.74%	-40.19%	33.46%

Source: S&P Global Market Intelligence.